Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
AAPG Quote, Financials, Valuation and Earnings
Last price:
$23.52
Seasonality move
:
59.09%
Day range:
$22.70 - $24.43
52-week range:
$17.56 - $48.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
36.18x
P/B ratio:
96.71x
Volume:
2.4K
Avg. volume:
2.3K
1-year change:
31.13%
Market cap:
$2.3B
Revenue:
$136.3M
EPS (TTM):
-$2.01
Analysts' Opinion
-
Consensus RatingAscentage Pharma Group International Co., Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.14, Ascentage Pharma Group International Co., Ltd. has an estimated upside of 101.16% from its current price of $24.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing 100% downside risk from its current price of $24.43.
Fair Value
-
According to the consensus of 5 analysts, Ascentage Pharma Group International Co., Ltd. has 101.16% upside to fair value with a price target of $49.14 per share.
AAPG vs. S&P 500
-
Over the past 5 trading days, Ascentage Pharma Group International Co., Ltd. has overperformed the S&P 500 by 5.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ascentage Pharma Group International Co., Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ascentage Pharma Group International Co., Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Ascentage Pharma Group International Co., Ltd. reported revenues of --.
Earnings Growth
-
Ascentage Pharma Group International Co., Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ascentage Pharma Group International Co., Ltd. reported earnings per share of --.
Enterprise value:
2.2B
EV / Invested capital:
--
Price / LTM sales:
36.18x
EV / EBIT:
--
EV / Revenue:
41.07x
PEG ratio (5yr expected):
-1.73x
EV / Free cash flow:
-59.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$38M
Return On Assets:
-14.84%
Net Income Margin (TTM):
-297.08%
Return On Equity:
-109.51%
Return On Invested Capital:
-19.66%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-03-15 | 2025-03-15 | 2025-03-15 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $247.2M | $278.4M | $242.7M | $270.2M | -- | |
| Total Assets | $372.5M | $452.9M | $402.3M | $427.5M | -- | |
| Current Liabilities | $30M | $91.4M | $88.6M | $146.6M | -- | |
| Total Liabilities | $148.2M | $322M | $319.5M | $320.7M | -- | |
| Total Equity | $224.3M | $130.8M | $82.7M | $106.8M | -- | |
| Total Debt | $100M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-03-15 | 2025-03-15 | 2025-03-15 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
AAPG
Sector
Market Cap
$2.3B
$25.1M
Price % of 52-Week High
50.42%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-3.8%
-1.6%
1-Year Price Total Return
31.13%
-18.38%
Beta (5-Year)
--
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$23.57
200-day SMA
Sell
Level
$33.23
Bollinger Bands (100)
Sell
Level
24.5 - 32.42
Chaikin Money Flow
Buy
Level
1.2M
20-day SMA
Buy
Level
$23.96
Relative Strength Index (RSI14)
Buy
Level
51.38
ADX Line
Sell
Level
28.71
Williams %R
Neutral
Level
-24.0024
50-day SMA
Sell
Level
$25.08
MACD (12, 26)
Sell
Level
-0.33
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
1.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-2.9891)
Sell
Beneish M-Score
(Annual)
Level (-0.7016)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.5962)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Stock Forecast FAQ
In the current month, AAPG has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AAPG average analyst price target in the past 3 months is $49.14.
-
Where Will Ascentage Pharma Group International Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ascentage Pharma Group International Co., Ltd. share price will rise to $49.14 per share over the next 12 months.
-
What Do Analysts Say About Ascentage Pharma Group International Co., Ltd.?
Analysts are divided on their view about Ascentage Pharma Group International Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ascentage Pharma Group International Co., Ltd. is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Ascentage Pharma Group International Co., Ltd.'s Price Target?
The price target for Ascentage Pharma Group International Co., Ltd. over the next 1-year time period is forecast to be $49.14 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AAPG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ascentage Pharma Group International Co., Ltd. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AAPG?
You can purchase shares of Ascentage Pharma Group International Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ascentage Pharma Group International Co., Ltd. shares.
-
What Is The Ascentage Pharma Group International Co., Ltd. Share Price Today?
Ascentage Pharma Group International Co., Ltd. was last trading at $23.52 per share. This represents the most recent stock quote for Ascentage Pharma Group International Co., Ltd.. Yesterday, Ascentage Pharma Group International Co., Ltd. closed at $24.43 per share.
-
How To Buy Ascentage Pharma Group International Co., Ltd. Stock Online?
In order to purchase Ascentage Pharma Group International Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AAPG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AAPG
Sector
P/E ratio
--
21.37x
PEG ratio
-1.73x
-0.01x
P/B ratio
96.71x
1.73x
Price / LTM sales
36.18x
1.46x
Growth Metrics
AAPG
Sector
Revenue growth
--
3.27%
Earnings growth
--
12.13%
Revenue (5-year growth)
130.37%
6.25%
Earnings forecast
-$0.40
-$0.20
Profitability
AAPG
Sector
Profitability FY 2024
$120.4M
$2.3M
Return on invested capital
-19.66%
-33.43%
Return on assets
-14.84%
-29.94%
Return on equity
-109.51%
-40.07%
Earnings Date
Last Earnings Date
Aug
20
Next Earnings Date
Mar
25
Estimated Next Earnings Date
Nov
19
Balance Sheet
AAPG
Sector
Total cash
$172.8M
$24.9M
Short term investments
--
$23M
Total assets
$359.6M
$70.1M
Long term debt
--
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
56
ORKA alert for Mar 15
Oruka Therapeutics, Inc. [ORKA] is up 16.04% over the past day.
Buy
100
APEI alert for Mar 15
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Sell
40
GDXD alert for Mar 14
MicroSectors Gold Miners -3X Inverse Leveraged ETN [GDXD] is up 26.02% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
